GAITHERSBURG, Md., May 5 /PRNewswire-FirstCall/ -- Digene Corporation today announced it plans to host an analyst breakfast meeting entitled "Establishing a New Standard of Care" in Washington, D.C. at 7 a.m. ET May 9.
Featuring Thomas Wright Jr., MD, Professor in the Division of Gynecologic Pathology College of Physicians and Surgeons, Columbia University, an internationally recognized expert on HPV vaccines and members of Digene's management, the breakfast meeting will also provide a question & answer session for financial analysts.
Members of Digene's management team will also discuss the emerging status of HPV testing as standard of care and the anticipated impact of HPV vaccines on the cervical cancer screening paradigm, as well as provide an update on Digene's direct-to-consumer and physician education campaigns.
The discussion will be broadcast live on Digene's Web site (http://www.digene.com/ ), and will be archived until June 9, 2006. To register for the event, contact Courtney Wen at (212) 850-5622 or
About Digene
Digene Corporation , based in Gaithersburg, MD, develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases -- with a focus on women's cancers and infectious diseases. The company's hc2 High-Risk HPV DNA Test(R) is the only test for human papillomavirus approved by the U.S. Food and Drug Administration (FDA), for both follow-up evaluation in women with inconclusive Pap results and for primary adjunctive screening with the Pap test in women age 30 and older. For primary adjunctive screening, it is marketed as both The Digene HPV Test and the DNAwithPap(R) Test. These brand names do not refer to the Digene product that tests for several types of the virus commonly referred to as "low-risk HPV," which are not associated with cervical cancer. For more information, visit http://www.thehpvtest.com/ . Digene's HPV test is also CE-marked in Europe both routine, primary screening and follow-up evaluation of women with inconclusive Paps. It is marketed in more than 40 countries worldwide. In addition, Digene's product portfolio includes DNA tests for the detection of other sexually transmitted infections, including chlamydia and gonorrhea, as well as tests for blood viruses. For more information, visit the company's Web site, http://www.digene.com/ . Investors also may contact Charles Fleischman at (301) 944-7000; journalists may contact Pam Rasmussen, (301) 944-7196.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the Company's actual results to vary materially from those indicated by such forward-looking statements. Meaningful factors, which could cause actual results to differ from expectations include, but are not limited to, the degree of acceptance of HPV testing by physicians, uncertainty of the company's future profitability, its ability to scale up manufacturing operations to meet any increased demand, the uncertainty regarding patents and proprietary rights, the success of the Company's marketing efforts, competition, risks inherent in international transactions, and the inability to obtain requisite additional financing, as well as other factors discussed in the Company's Securities and Exchange Commission filings. For other factors, reference is made to the discussion in the Company's annual and quarterly reports filed with the Securities and Exchange Commission.
